1. �й�ҽѧ��ѧԺƤ����ҽԺ���о�����
2. �Ͼ� �й�ҽѧ��ѧԺ����Э��ҽѧԺƤ�����о���

����ϩ��ǿЧ������֢���ʣ��������ϲ���Ƥ�������Լ����ķ�������չ��Ȼ������ϩ�����׿�������³˾�أ����ڹ�����Ƥ���������е����������û����в��ꡣĿǰ�й���³˾�ص�����о��϶࣬�������һ���о���ʾ����³˾�ضԶ�ͯ���ж���Ӧ��Ƥ����Ч�����Գ������ض���Ӧ��Ƥ������������Ч�����ɸ��ƻ��ߵ�˯�ߺ�������������³˾�������鰷H1�����׿����䲻�ܼ�������ݡ����ķ����������������Ը��ƻ����ٴ�֢״����������������³˾�ؾ������õ������Լ���ȫ�ԣ���ˣ��Դ�ͳ���Ʒ�����Ч��ݡ�������Ӧ��Ƥ�׻��߽Կɳ���ʹ�ø�ҩ���ơ�

Leukotrienes ��LTs��, a potent biological mediator, participate in the development of allergic dermatoses by binding to their receptors. Montelukast is a leukotriene receptor antagonist used in the treatment of allergic dermatoses. However, the therapeutic mechanisms of leukotriene receptor antagonists remain unknown. There have been numerous studies on montelukast, but the results are varying and somewhat contradictory. Studies have demonstrated that montelukast is effective for the treatment of mild to moderate atopic dermatitis in children, and can improve the sleep and inflammatory symptoms in adult patients with moderate to severe atopic dermatitis regardless of their poor response. Though the combination of montelukast and H1 receptor antagonists can not reduce the number of urticarial episodes, they markedly improve the clinical symptoms and quality of life in patients with chronic urticaria. On account of the good tolerability and safety, montelukast may be attempted in patients with urticaria and atopic dermatitis unresponsive to conventional therapy.